AbCellera Biologics Inc. (Nasdaq: ABCL) has priced an oversubscribed public offering of common shares and pre-funded warrants, expecting to raise approximately $200 million in gross proceeds before underwriting discounts, commissions, and estimated offering expenses.

The Vancouver-based clinical-stage biotechnology company is offering 17,435,897 common shares at $9.75 per share. In lieu of common shares, certain investors may purchase pre-funded warrants to acquire up to 3,076,926 common shares at $9.74999 per warrant, which equals the per-share offering price minus a $0.00001 exercise price. All shares and warrants are being sold by AbCellera.

The offering is expected to close on August 14, 2026, subject to customary conditions.

AbCellera said it intends to use net proceeds to fund research, development, and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and general corporate purposes.

Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets are serving as joint book-running managers for the offering.

The securities are being offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission on February 27, 2025. The company noted that no securities are being offered or sold in Canada or to Canadian residents.